2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Multiple Myeloma
181
Recurrence
32
Neoplasms, Plasma Cell
16
Lymphoma
11
Waldenstrom Macroglobulinemia
6
Neoplasms
6
Lymphoma, Mantle-Cell
6
Lymphoma, Non-Hodgkin
5
Lymphoma, Large B-Cell, Diffuse
5
Smoldering Multiple Myeloma
4
Leukemia
4
Small Cell Lung Carcinoma
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Lymphoma, T-Cell, Peripheral
3
Lymphoma, B-Cell, Marginal Zone
3
Leukemia, Plasma Cell
3
Hodgkin Disease
3
Hematologic Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Ovarian Neoplasms
2
Mycosis Fungoides
2
Lymphoma, T-Cell, Cutaneous
2
Lymphoma, T-Cell
2
Leukemia, Myeloid, Acute
2
Kidney Neoplasms
2
Disease
2
Uterine Cervical Neoplasms
1
Stomach Neoplasms
1
Sezary Syndrome
1
Salivary Gland Adenoma, Pleomorphic
1
Interventions
Lenalidomide
2
Dexamethasone
2
Bortezomib
2
ruxolitinib
1
posaconazole
1
darinaparsin
1
carfilzomib
1
belinostat
1
Stem Cell Transplantation
1
SCIO-469
1
Low-Level Light Therapy
1
Hydroxyurea
1
Cyclophosphamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Bone Marrow Neoplasms
×
carfilzomib
×
Clear all
NCT03859427
2024-08-13
ARROW2
Amgen
Phase 3
Completed
454 enrolled
24 charts